codeveloping alongside chemistry and in vitro screening, compound management was one of the first areas in research recognizing the need for efficient processes and workflows. material management groups have centralized, automated, miniaturized and, importantly, found out what not to do with compounds. While driving down cost and improving quality in storage and processing, researchers still face the challenge of interfacing optimally with changing business processes, in screening groups, and with external vendors and focusing on biologicals in many companies. Here we review our strategy to provide a seamless link between compound acquisition and screening operations and the impact of material management on quality of the downstream processes. although this is driven in part by new technologies and improved quality control within material management, redefining team structures and roles also drives job satisfaction and motivation in our teams with a subsequent positive impact on cycle times and customer feedback. (Journal of Biomolecular Screening 2009:485-491) 
INTRODUCTION
M aterial management is a core discipline underpinning a variety of functions within early drug discovery, and compound collections represent a key asset and a significant investment for a pharmaceutical company. methods and processes to handle this asset have evolved around 2 main themes: compound stewardship (i.e., storing and processing of compounds under conditions that are optimal for integrity and efficient use) and making compounds accessible throughout all stages of drug discovery. compound stewardship has initially focused on volume reduction during compound preparation to maximize the lifetime of compound stocks. an altered approach to storage-for example, through the introduction of storage concepts that avoid multiple freeze-thaw cycles by using "oneuse" sample aliquots 1 -has been adapted to maximize the integrity of the samples.
progress with respect to rapid sample access, storage, and distribution has been driven by the requirement of highthroughput technologies applied to upstream and downstream processes (e.g., combinatorial chemistry, high-throughput screening [Hts] , and other high-throughput biological experimentation). the demands of modern Hts and approaches requiring large cherry-picking capabilities (e.g., iterative and knowledge-based screening approaches) have driven automation in sample management. 1, 2 this, in turn, has highlighted shortfalls in other areas-for example, the speed at which new compounds enter the process and the need for efficient processes supporting hit-to-lead and lead optimization. 1 today, the availability and distribution of samples are supported with information technology (it)-based ordering and inventory applications akin to systems applied to mail-order and supermarket logistics.
With numbers no longer the main bottleneck, we have discovered an array of challenges relating to the processing and storage of compounds: the stability of compounds in solution, [3] [4] [5] solubility, 6 establishing accurate sample concentrations, 7 and adsorption and carryover 4 in all processing steps, to name but a few. these findings underline the crucial role of material management operations and the impact of compound handling on data quality in all scientific experiments, 6 but this is not always recognized and reflected in the organizational approach.
With growing knowledge (often through trial and error), we have a much better understanding of underlying principles, but we are not in a position to start again, and we rely on legacy systems and procedures that affect the speed and direction of any change we might wish to make. consequently, there is no single right solution, neither in scientific nor in organizational aspects. in this article, we discuss our strategy to support lead optimization at pfizer sandwich, focusing on the organization of teams supporting compound handling and our efforts to close the gap between material management and its customers.
SUPPORTING LEAD OPTIMIZATION
Hts has had a major impact on our work and has driven the introduction of automated liquid stores holding small, singleuse aliquots of compounds to enable rapid hit confirmation and exploratory medicinal science, pfizer global research and development, sandwich, united Kingdom. the assay lab from compound preparation tasks, we have harmonized sample processing to a high degree, taking into account learnings and reducing errors due to variation in sample handling.
one of the major challenges has been the integration of a high number of different inputs. samples arrive from the pfizer dry store, from our autopurification system, as dry submission from the chemist, and, more recently, from a wealth of external contract research organizations and collaborators. after initial processing, samples are "consolidated" into our local, liquid store, and all subsequent requests are made against this store. material management teams have to deal with this variation, so the customer should "just order" and does not need to know about the effort "behind the scenes." so although we may be able to turnaround the majority of samples on the same day, different timelines depending on sample origin can lead, if not managed, to fragmented order fulfillment, causing inefficiency and duplication in the assay labs and frustration of longer lead times for results. the output for each supported project is predefined and captured by the biologist upfront (in a predefined "screen panel"), specifying volume, concentration, layout of plates, and standards to be included for the various screens to which the compound is to be submitted. although ad hoc ordering of a simple aliquot is possible, >90% of compound orders are now against screen panels and specific processing templates, with the remainder being samples for shipment to collaborators and pfizer sites not aligned to the bespoke output of the sandwich compound logistic process.
NEW ORGANIZATIONAL STRUCTURE AND WORKING PARADIGMS
our material management strategy has focused on centralization, to drive economies of scale by combining tasks and to facilitate the standardization and automation of all aspects of the workflow. this strategy has been very successful, bringing efficiency and reducing timelines. However, without further investment into equipment and human resource, the current approach presents a barrier to further progress in 2 core dimensions: cycle time and quality of deliverables.
our approach to quality has initially focused on inspection and control. With the automated workflows, we have started to tackle the root causes of existing problems through errorproofing process steps and a quality control (Qc) process focusing on the overall sample workflow rather than the Qc of single machines. more inspection and control is costly and technically challenging, and we believe the solution to total quality management 8 is in the redesign of the existing tasks. Within material management, we have divided the process into separate tasks that are highly standardized and executed independently. this focus has enabled high throughput and rapid integration of new starters with less training and, often, follow-up. 1 High numbers of samples are requested, and there is little variation in output formats. supporting lead optimization has a different requirement set, not least the need for a much higher storage volume to support secondary assays in a 96-well format, ex vivo experiments and admet assays, and customized outputs for the different assay types. at sandwich, the overall goal is to implement an automated workflow from sample ordering to delivery, just in time and as assay-ready samples. Figure 1 provides an overview of the essential system components, rather than highlighting specific technologies or equipment integrated, as the principle should hold independent of the specific execution. freeing the biologist in High-level process view of the sandwich compound logistics workflow supporting the iterative lead optimization process. solubilization: resolubilization of dry compounds submitted by chemists aided by sonication; cherrypicking: selecting compounds from the local store or an input plate according to the customer order; serialization: providing a series of compound dilutions either within a plate or across multiple plates; replication: producing multiple copies of a serialized plate to support multiple screens (e.g., selectivity screening). lower qualifications. Without an upfront training burden, staff is productive within a single day. However, this efficiency has been at the cost of "deskilling" of jobs and reduced ownership with respect to the task and problems. as a counter to this, we have introduced "swimlaning," where each order is processed from start to finish by one colleague. the output is a recognizable "product" and links the material management colleague to the project/customer, increasing quality (errors are recognized and owned), enabling more efficient troubleshooting, and, importantly, increasing motivation in the team.
reducing cycle time from compound submission to data publication has been a key driver within sandwich, with the overall aim to increase the number of iterative synthesis and testing loops within the project year. timings for material management and screening activities typically only reflect around one third of the overall cycle time from compound design to data. nevertheless, there is ample opportunity to reduce processing times, especially where waiting times have been unintentionally introduced, due to a work organization where the overall process spans different teams and lines. teams in material management and screening worked individually to reduce timelines, but this silo-optimization exposed the handover point between compound logistics and assayist as the longest waiting time, accounting for nearly a quarter of the overall cycle time ( Fig. 2a ). although we have initially tried to better align both teams, the focus on logistics has been intensive on organizational aspects, and a lot of effort is needed establish a process that tries to bring together multiple resources at a specific, predefined time. consequently, we are currently piloting hybrid roles, where a scientist prepares compounds and runs the assay, starting the process only when all resources are aligned. at first glance, this may appear to be a step back from the centralized model, but it is important to note that we do this after standardizing and automating all process steps. the prework of the material management team has established best practice and processes and enables this new working paradigm. first results of this pilot indicate that we can reduce waiting time ( Fig. 2b) and again increase quality, as the impact of problems in plate processing can be better assessed by the scientist running the assay. although the process is widely applicable, it is most efficient for smaller orders and multiple screening cycles per week and will operate in parallel rather than replace the routine material management processes.
IMPACT OF MATERIAL MANAGEMENT PROCESSES ON DATA QUALITY
Quality enhancements within compound handling translate directly into improved data quality in biological testing. although we typically think of Qc of equipment (applied for single machines and also as process Qc, where the cumulative impact of the combined processing steps is tested), in our experience, it has been more crucial to look at the fundamentals of the process. a key aspect to a quality output has been the adaptation of compound processing to use 100% dmso from storage to serialization. compared to a process transferring compounds to an aqueous environment before serialization, data now show less variation and better reproducibility. although in some cases, potency changes in either direction have been observed, these have been a consequence of the nature of the chemical matter, and the quality has generally increased, as exemplified in Figure 3 .
another frequently overlooked aspect (or deemed obsolete with respect to the advance of contact-free dispensing technologies) is the wash protocols applied during compound processing. multiple wash cycles using appropriate solvent are crucial to prevent carryover, but results are not always welcomed by the chemist as we have found an apparent reduction in potency by applying more stringent routines (using extensive washes with 100% dmso) in a number of projects. 
CLOSING THE GAP WITH ASSAY-READY PLATES
Hardly more than 5 years ago, project chemists would routinely hand-deliver newly synthesized compounds to their biology counterpart. in this short space of time, we have centralized and standardized compound preparation tasks, making gains in both efficiency and quality. the culmination of this improved support lies in the provision of assay-ready plates-a deliverable ready for assay with no additional handling steps required of the assayist. this effort has been driven by analysis of problems related to practices where compounds, controls, and standards on a plate are handled in different ways by different people and by the demand of customers in the screening groups. assay-ready plates provide clear benefits:
· there should be a significant time saving for assayists.
When mother solutions are delivered, postprocessing can take a considerable proportion of the total assay time. By delivery of a low volume in 100% dmso, assayists can dilute (with buffer) their compound directly in the assay plate as the first step of the assay, thus removing several handling steps. compared with the existing processes, we estimate a time savings of 2 to 3 full-time equivalents (ftes) for our screening group.
· less compound should be consumed.
Where some compound sets are in short supply, only the amount of compound actually needed in the assay can be dispensed.
· data quality should be improved.
We know from our own experience and literature reports 6,9 that preserving compounds in 100% dmso right up to the time of assay is critical to providing tight data and following true structure-activity relationships (sar). Without many exceptions, current large-volume delivery techniques require the end user to dilute compounds in aqueous buffers at a relatively early stage and use additional transfer steps to produce their final assay plate. this can result in compound precipitation and expose the dilution steps to compound carryover and reduced data reproducibility.
· true process screen controls should be enabled. previous methods required the assayist to add reference compounds to partially processed plates already containing the novel compounds with a potential for a mismatch of sample and control composition. 10 We required that the same protocol as for unknowns be used to add 100% dmso standards and controls so that the assays now have a true process control.
time-saving and compound-saving aspirations have been simple to measure and confirm, and the popularity of assayready plates among assayists speaks to the time that it saves for them. positive customer feedback has been one of the unanticipated but very welcome spin-offs from the new process. for compound subsets used by multiple projects and hence in short supply, we are able to use significantly less sample while still addressing all of the screen's requirements. for example, we have recently supported 7 fragment screens using less than 3.5 µl of a 30-mm working stock. 3. impact of material management processes on data quality in screening. a selected set of compounds with varying potencies and chemical properties has been analyzed in a cell-based assay following a protocol keeping compounds in 100% dmso from cherry-picking to serialization (dmso process) and a protocol serializing compounds in an aqueous environment (10% dmso, aqueous process). there is clearly a greater variability in data produced using the aqueous process (experiments 1 and 2 for each condition have been run within the same assay run).
although time saving and customer satisfaction are very welcome, the new process would not be viable if data quality suffered, but we are able to demonstrate tangible improvements to data quality in many of the assays supplied ( Fig. 4) , much of which we ascribe to a thorough testing of the protocols against real compound runs, using the same plate types, a wide range of compound classes, and a sensitive Qc method during protocol development. this improvement is not only visible in Z′ factors but also when measuring the quality of curves, as assessed by the number of outliers removed or the error of the derived ic 50 values (e. g., Fig. 4b ). although we have not completed a complete statistical analysis across all projects, the feedback from projects chemists underlines the impact and validity of the new approach from a customer perspective.
IMPACT OF OUTSOURCING
the growth in outsourcing of routine work to cost-effective contract research providers has affected materials management in both expected and unexpected ways. the offshoring of the pfizer dry store to sigma/aldrich in milwaukee (not a pfizerspecific strategy as outlined by meerpoel and colleagues 11 but beyond the scope of this article) has, due to a perception of easier and more timely access, focused customers in chemistry and biology on the use of locally stored liquid samples, a big change as previous analysis in other organizations has linked the likelihood of follow-up (e.g., from Hts hits) to the availability of a dry sample. 12 in the past, with each pfizer site maintaining its own dry file access to samples for in vivo testing and for the more compound-intensive in vitro testing, work would have automatically defaulted to the dry store. service was rapid and required little forward planning by the scientist. delivery of dry sample orders from the outsourced store is achieved in a very reasonable 3 days (for the united Kingdom, with shorter times in the united states), but even this rapid service has driven an increase in the number and type of experiments for which scientists will now consider using a liquid sample. in many cases, the routine supplied concentration of 4 mm is not compatible with the experimental system due to the dmso vehicle or simply due to the desired top concentration for testing, and this has driven the introduction of high-volume and concentration samples into not only our local store but also, following proof of demand and concept, the sandwich remp repository from where these samples are available globally.
the outsourcing of chemistry for hit to lead and lead optimization is now a routine tool 13 but has generated multiple compound streams that have to be consolidated with samples from in-house efforts. the challenge is not the physical processing (although this can be frustrating if acceptable input formats have not been agreed on in advance) but the timely registration requiring data transfer relating to structures and quality of samples, which are a prerequisite for processing in our automated sample workflow and all subsequent steps in FIG. 4. impact of assay-ready plates. (a) shown is an example demonstrating the improvement in data quality (as measured by the Z′ prime) following the introduction of assay-ready plates incorporating the delivery of controls and standards. Bravo prepared: plates prepared in the new process, adding all controls and standards in the material management group; normal Hta: compounds prepared by material management and controls and standards added by the screening scientist in a separate step; Hta: high-throughput assay, 360 compounds at a single concentration. (b) example analysis of curve quality. for a cell-based assay, 150 ic 50 curves derived from assay-ready plates or standard plates (further processing in the screening laboratory) have been analyzed. the curve quality has been judged by the number of outliers removed during automated fitting and the coefficient of variation (cV) on the calculated ic 50 . for this analysis, individual curves have been assessed to establish the percentage of outliers and %cV of the fitted ic 50 . to summarize individual results, percentage results for each curve have been added to establish a total cumulative value across all 150 curves for each condition. screening. starting with incoming samples, the focus on external collaborations within the therapeutic areas has moved on to feature also increased numbers of outgoing samples requiring customized formats to suit the processes of individual collaborators. as material management groups are often not included at the onset of discussions, we routinely encounter problems in aligning output formats with academic and industrial collaborators. simple 2-way exchanges have been only the start, and we now see examples of multiple handovers where the synthesis of intermediates, compounds, and the different testing regimes is no longer colocated but divided between 3 or 4 separate locations. although these activities can add business value in multiple dimensions (cost, access to new technologies, scientific expertise), they have created complex workflows with multiple opportunities for misalignment and error. they require not only altered physical processes to deal with them but also additional it resource to allow sharing of data and information, often separated from the bulk of our data storage systems for security reasons, but at the same time accessible for the individual project to allow access for combined processing and data visualization for the project scientist.
FUTURE DIRECTIONS FOR MATERIALS MANAGEMENT
materials management processes have changed remarkably over the past several years, as we have learned how to become more efficient and, perhaps more important, what not to do. the majority of the changes to our processes and techniques have been reactive, designed to better respond to customer requirements in terms of capacity, throughput rate, and turnaround time and designed to care better for the compounds we are handling so that the quality of the product we deliver is improved. this reactivity is exactly as it should be because materials management is of no real use of itself but is there to provide service and support to screening and chemistry design. nevertheless, we should see it as part of our remit to look ahead and try to anticipate the future requirements of our customers so that we can respond more quickly. · We should be open to new storage formats, new output formats, and provision of new services where these would be beneficial to our customers. increasing desire to outsource the synthesis of compounds, as well as the screening of the file (i.e., pfizer compound collection for Hts), means collaborating with vendors who often will prefer different layouts, concentrations, and storage media than those we consider as standard. · further reductions in the amount of each compound that is synthesized seem inevitable on economy grounds, particularly when customs duties are levied according to quantity on incoming compounds synthesized at a far-shore vendor.
But will we be required to handle ever smaller quantities of compound? likely not, for we are already able to dispense accurately a sufficiently small amount of material to enter directly into the majority of assays. there is no need to go smaller within the next 2 to 3 years, as limitations in other processes (e.g., within screening processes in adme and collaborations with external partners) prevent a translation of this increased effort into overall efficiency. · some years ago, compound synthesis to order was predicted so that materials would go straight from the chemistry lab to the screen-no storage required or intended-because ad hoc repeat synthesis would be more economical and convenient than storage and reuse. this would certainly have reduced issues around stability of stored compounds and inventory management, as well as neatly avoid potential waste in synthesizing sufficient compound to carry through the entire raft of in vitro screening when we know that most compounds fail at the first hurdle. this innovation has not been put into practice, and the assay-ready plate seems convenient enough to ensure that there is insufficient benefit in going down this route for conventional screens. if the difficulties associated with small-scale synthesis and processing are ever to be overcome, the closest one can imagine reaching an integrated synthesis and screen paradigm lies in the marriage of flow chemistry 14 and microfluidic screening, 14, 15 but there is no hint yet that the union is close or will have sufficient return on investment. · We check the purity of the newly synthesized compound, and currently measurement of the purity and concentration is possible only at concentrations involved in storage solutions. although it is a goal to measure concentrations in the final assay sample, with no single analysis method capable of detecting all compound classes, this seems still a way off. · the current desire of most pharma to expand their portfolio in terms of biological agents (modified sirna, antibodies, antibody-compound conjugates, etc.) will challenge materials management to adopt new storage methods and altered dispensing techniques to handle this different range of samples often requiring quite different handling. acoustic dispensing offers the chance of noncontact dispensing, which will be valuable for the most sensitive biological reagents if problems of evaporation and stability can be overcome. dmso may no longer be a suitable universal solvent. is this the time to revisit solvents even for smallmolecule libraries and accept that one size never did fit all?
CONCLUSIONS
no matter how well we anticipate, we will always have to be able also to react quickly to unexpected requirements, and materials management teams have shown themselves to be good at this. the biggest hurdle to the successful introduction of radically new technologies is, and probably always will be, the difficulty in integrating these alongside existing methods and equipment. it is not possible to throw away everything and
